Innovation without borders
Our research and development teams across Japan, Europe and the US design next generation diagnostic solutions, from neurological biomarkers that are transforming Alzheimer’s disease care to ultra-sensitive detection platforms that expand diagnostic accuracy across a wide range of conditions. With more than 12% of base revenue invested in R&D, we remain at the forefront of diagnostic assay innovation.
Across the world, we prove that our innovations work in real clinical practice through partnerships with leading laboratories, including extensive use of our fully-automated Lumipulse® chemiluminescent enzyme immunoassay (CLEIA) platform. This real-world validation gives our global CDMO partners confidence that our diagnostic solutions will perform reliably in their markets.
Related links:
Leading the neuro revolution
Nowhere is our impact more visible than in the field of neurological disease diagnostics. Our work builds on decades of innovation – starting with the CSF-based expertise gained through the acquisition of Innogenetics in 2010 and evolving to today’s blood-based breakthroughs such as the FDA-cleared Lumipulse® G pTau 217/β-Amyloid 1-42 Plasma Ratio in-vitro diagnostic test. With the added strengths brought in through the acquisition of ADx NeuroSciences, we continue to develop novel biomarkers that enable simpler, less-invasive diagnosis of neurodegenerative diseases.
Our neurological biomarker pipeline extends far beyond Alzheimer’s disease including biomarkers for conditions such as multiple sclerosis (MS), Parkinson’s disease, and other motor neuron diseases such as amyotrophic lateral sclerosis (ALS) – creating the marker portfolio that will define brain health diagnostics and neurodegenerative disease testing for the next decade.
Related links:
Open partnership model
What makes us different is how we share innovation. While others guard their technology carefully, we have embraced an open business model that prioritizes patient access over corporate boundaries. Our CDMO partnerships with leading diagnostic companies worldwide enable breakthrough diagnostics to reach global markets faster than ever before.
From supplying diagnostic raw materials and reagents to providing complete biomarker development, manufacturing, and regulatory services, we offer everything partners need to bring innovative diagnostics to their customers. This collaboration creates exponential impact – allowing our innovations to multiply across our own and partner diagnostic platforms, reaching millions more patients than we could serve alone.
Related links:
Environmental Health and Safety Policy
Fujirebio Diagnostics, Inc. management and employees are committed to protecting the environment, and the health and safety of all people working for or on behalf of our organization. Our Environmental Health and Safety Management System (EHSMS), provides the framework for developing objectives in support of continual improvement.
We maintain the effectiveness of our EHSMS by our commitment to:
-
Compliance – We are committed to complying with all applicable requirements.
-
Communication – We are committed to communicating the requirements of our EHSMS to all who are working for or on behalf of the organization.
-
Continual Improvement – We are committed to continually improving our environmental health and safety performance through developing objectives that are in line with our significant environmental aspects.
-
Prevention of Pollution – We are committed to preventing pollution through eliminating and/or reducing pollution at its source, and by promoting energy savings and recycling throughout the organization.
Employee participation is key to Fujirebio Diagnostics’ success as a safe workplace and as an effective steward of the environment.
Download Our ISO 14001:2015 Certificate
Fujirebio Diagnostics Inc. is an AdvaMed Certified Company
